A Phase Ib/Ⅱ Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of Recombinant Human NsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Patients with Recurrent/progressive High-grade Glioma
Latest Information Update: 16 Jan 2025
At a glance
- Drugs BioTTT 001 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Beijing Bio-Targeting Therapeutics Technology
Most Recent Events
- 01 Jul 2024 New trial record
- 04 Jun 2024 Status changed from not yet recruiting to recruiting, according to Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2024 Initial results (n=8) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.